Related Experiment Videos

Are there promising biologic therapies for osteoarthritis?

David J Hunter1

  • 1Division of Research, New England Baptist Hospital, 125 Parker Hill Avenue, Boston, MA 02120, USA. djhunter@caregroup.harvard.edu

Current Rheumatology Reports
|May 7, 2008
PubMed

Insights

Developing new osteoarthritis (OA) treatments requires understanding joint mechanics and pathophysiology beyond cartilage. Promising biologic therapies are emerging, but lessons from past interventions are crucial for their success.

Area of Science:

  • Biomedical Science
  • Orthopedics
  • Pharmacology

Background:

  • Osteoarthritis (OA) presents a significant unmet need for effective pharmacologic therapies.
  • Current OA treatment development must consider joint mechanics and the pathophysiology of affected tissues.
  • Understanding the role of non-cartilage tissues (bone, fat, synovium) in OA is key to therapeutic breakthroughs.

Purpose of the Study:

  • This review explores promising biologic therapies for osteoarthritis treatment.
  • It emphasizes the importance of integrating knowledge of joint pathophysiology into therapeutic strategies.
  • The review aims to guide future OA intervention development.

Main Methods:

  • Literature review of current and emerging biologic therapies for OA.
  • Analysis of the role of various joint tissues in OA pathophysiology.
  • Synthesis of lessons learned from previous OA therapeutic interventions.

Main Results:

  • Several promising biologic therapies are under investigation for OA.
  • Enhanced understanding of bone, fat, and synovium roles in OA is emerging.
  • Past therapeutic development provides critical insights for future OA treatments.

Conclusions:

  • Biologic therapies show promise for treating osteoarthritis.
  • Further research into the complex pathophysiology of OA, including non-cartilage tissues, is essential.
  • Effective future OA therapies depend on applying lessons learned from prior interventions.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...